Dr Lal PathLabs, one of India’s leading diagnostic service providers, on Thursday reported a healthy 24% year-on-year rise in consolidated net profit for the June quarter at ₹132 crore, up from ₹106.4 crore in the same period last year and ahead of street estimates of ₹122.76 crore.
Revenue for the quarter grew 11.3% to ₹670 crore, compared to ₹602 crore a year ago, also marginally beating expectations of ₹668.3 crore. The growth was largely driven by a rise in sample volumes, which increased 10.7% year-on-year to 23.4 million, while patient visits rose 6% to 7.6 million.
The company’s EBITDA for the quarter stood at ₹192.5 crore, marking a 13% increase over last year. Margins improved slightly to 28.73% from 28.34% a year ago, also surpassing expectations of 28.2%.
Dr Lal PathLabs said growth was supported by expansion in metro and Tier-I markets, as well as deeper penetration across Tier-III and Tier-IV regions. Preventive testing under its ‘Swasthfit’ portfolio contributed 27% of total revenues during the quarter.
The company ended the period with ₹1,229 crore in cash reserves.
In a move that will cheer shareholders, the board declared an interim dividend of ₹6 per equity share for FY26. The record date for the same has been fixed as August 6, 2025.
Following the announcement, shares of Dr Lal PathLabs were trading 1.46% higher at ₹3,144.20 on the NSE at 2:18 pm, after touching an intraday high of ₹3,153.90.
